×
ADVERTISEMENT

MAY 4, 2021

New PD-1 Jemperli Approved to Treat Mismatch Repair–Deficient Endometrial Cancer

The FDA granted accelerated approval to the programmed death receptor-1 (PD-1)-blocking antibody dostarlimab-gxly (Jemperli, GlaxoSmithKline) for adults with mismatch repair–deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or after a platinum-containing regimen.

The agency also approved the VENTANA MMR RxDx Panel (Roche) to identify patients with advanced or recurrent endometrial cancer who are eligible for treatment with dostarlimab.